PHARMACY

Teva appoints UCLA urologic oncology professor to board

BY Alaric DeArment

JERUSALEM — Teva Pharmaceutical Industries has added a University of California at Los Angeles medical professor to its board of directors, the Israeli drug maker said.

Teva announced the appointment of Arie Belldegrun, who is a director at the UCLA Institute of Urology Oncology and professor and chair of urologic oncology at the David Geffen School of Medicine. The company appointed Belldegrun at its Feb. 5 meeting to fill a vacancy, and Belldegrun’s term will extend the drug maker’s 2013 annual shareholder meeting.

"We are pleased to welcome Dr. Belldegrun to our board," Teva chairman Phillip Frost said. "Arie’s extensive experience in the pharmaceutical industry both as a doctor, a business leader and an academic will enable him to make significant contributions to the board immediately and help guide us as well look for new and innovative ways to bring medicines to patients around the world and continue to increase value for our shareholders."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Post-approval drug problems could be due to poor adherence in trials, study finds

BY Alaric DeArment

MCLEAN, Va. — Unexpected toxicities from prescription drugs that emerge years after regulatory approval may be due to poor medication adherence in clinical trials, according to a new study.

While much attention on medication adherence has focused on patients not taking the already approved drugs prescribed to them or not taking them properly, the new study, released Tuesday by Consumer Health Information, found problems with adherence in clinical trials as well.

"Patient adherence in clinical trials must always be higher than that of the general population," Consumer Health Information president and CEO Dorothy Smith said. "Our challenge is to get patient adherence in clinical trials up to 95% so patients can be assured it is safe to take the FDA-approved dose."

According to the study, which looked at data from over the past 20 years, patient adherence wasn’t monitored between 1997 and 1999 in 53% of clinical trials of drugs that are still on the market today. Meanwhile, up to 30% of study patents did not take the full dosage, and patients could not understand 35% to 94% of informed consent documents. At least half of patients didn’t tell the study team that they had missed doses, and many did not realize that missing doses could endanger the lives of millions of people after a drug’s approval because undetected poor adherence could result in inaccurate dosing.

Smith recommended that clinical trial investigators develop adherence strategies and integrate behavior modification; determine how many doses of each drug can be missed without jeopardizing the therapeutic outcome; include patient adherence results as an outcome of the clinical trial and publish it in the package insert; create informed consent and patient-friendly programs that patients will understand; and gain patient trust so they provide honest feedback about any problems they have.

Unexpected toxicities have resulted in the FDA cutting drug dosages and withdrawing approval for others, but may be occurring because patients in the general population are more adherent than those in the clinical trials.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Tough new regulations for compounding pharmacies could be on the way, attorney says

BY Alaric DeArment

WASHINGTON — Massachusetts and New Jersey lately have been cracking down on sterile compounding pharmacies alleged to violate safety regulations, but the crackdown may soon go nationwide, predicted a legal firm focused on the matter.

LeClairRyan attorney Michael Ruggio said officials in several states were increasing scrutiny of compounding pharmacies in the wake of an outbreak of fungal meningitis linked to the New England Compounding Center, which so far sickened 696 people and killed 45, according to the Centers for Disease Control and Prevention.

"Our team has already received calls from compounding pharmacies in states such as Colorado, Minnesota and Pennsylvania," Ruggio, leader of LeClairRyan’s compounding pharmacy investigation and litigation team, said. "They are receiving warning letters from their state boards of pharmacy, and in one state, a prosecutor is exploring whether to file criminal charges for alleged safety violations. The takeaway here is clear: The meningitis outbreak amounts to a game-changer for compounding pharmacies everywhere; this sector will never be the same."

Meanwhile, Food and Drug Administration commissioner Margaret Hamburg in November 2012 called for FDA oversight of compounding pharmacies, while earlier that month, Rep. Edward Markey, D-Mass., proposed legislation to strengthen the federal government’s ability to regulate compounding and end the "regulatory black hole."

"Because compounding pharmacies can be lucrative, it is not unusual for conventional pharmacies to attempt to pursue this line of business," Ruggio said. "As a result of the outbreak, however, this is going to become far more difficult to accomplish. States are going to be rolling out new hoops and hurdles related to licensure, and the federal government might well end up subjecting compounding pharmacies to the stringent regulations that now apply to mainstream pharmaceutical companies, radically altering the cost-benefit analysis."

Possible regulations, Ruggio said, include unprecedented whistleblower protections and new fines and penalties for specific violations. All of these could have huge implications, he said.

"Remember, compounding pharmacies serve a big purpose," Ruggio said. "For those people who have allergies and sensitivities with regard to some mainline drugs, these companies can literally be a lifeline. Typically, these are not massive pharmaceutical companies. Excessive regulation could drive a lot of them out of business. Alternatively, it could drive the costs of their products too high, adding yet another burden to our already overburdened healthcare system."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?